An interventional study in which participants affected with Karappan Eczema will be treated with Gowri chindamani chendooram Internal and Karappan thylam External for the treatment of Karappan Eczema

An Open Clinical Trial to evaluate the effectiveness of Siddha formulation Gowri Chinthamani Chendooram Internal and Karappan thylam External in the management of Karappan Eczema amoung outpatients attending Ayothidass Pandithar Hospital National Institute of Siddha Chennai 47 - Nil

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/080440

Enrollment

Registered

2025-02-12

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L309- Dermatitis, unspecified

Interventions

Intervention1: Gowri chindamani chendooram (internal) and Karappan thylam (external): Internal medicine 200 mg bd with thirikadugu chooranam and honey and external medicine twice a day for 40 days Con

Eligibility

Inclusion criteria

Inclusion criteria: Participants having signs and symptoms of Karappan. Participants having duration of illness lesser than one month (acute Eczema). Participants having EASI SCORE lesser than 51. Participants willing to give blood samples for the investigations required

Exclusion criteria

Exclusion criteria: Pregnant and Lactating. Participants having secondary infection, bleeding disorder, diabetes mellitus, heart disease, tuberculosis,leprosy,scabies and psoriasis. Participants having fasting blood glucose level greater than 200 mg/dl and post prandial blood glucose level greater than 300mg/dl.Known hypertensive participants with blood pressure level greater than 140/90mm Hg.

Design outcomes

Primary

Measure	Time frame
Reduction of 30% in clinical signs and symptoms of Karappan which is assessed by using Eczema Area And Severity Index (EASI)Score after treatmentTimepoint: 3 months - patient screening. 7 months - patient enrollment. 2 month - outcome assessment.	—

Secondary

Measure	Time frame
The following data will be documented before and after treatment, Changes in complete haemogram, Total RBC, total WBC, DC, ESR) and Changes in liver function test (serum total bilirubin, direct bilirubin, indirect bilirubin, SGOT, SPOT, alkaline phosphatase and gamma GT)Timepoint: 3 months - patient screening . 7 months - patient enrollment. 2 months - outcome assessment	—

Countries

India

Contacts

Public ContactDr Yazhini S

National Institute of Siddha

drmanjarimd@gmail.com8056903083

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026